575 - PREFER-LA: Improved Adherence and Viral Control in Real-World Study of People with HIV (PWH) in the United States with Adherence Challenges on Oral Antiretroviral Therapy (ART) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA)

Presenting Author(s)

• 

  William R. Short, MD (he/him/his)

  Associate Professor of Medicine
  University of Pennsylvania
  Philadelphia, PA, United States

  Slides

Co-Author(s)

• RG

  Rebecca Glassman, MD

  Westchester Medical Center Health Network
  Hawthorne, New York, United States
• CH

  Christina Harbison, PharmD

  Clinical Pharmacist
  Prism Health North Texas
  Dallas, Texas, United States
• MW

  Mitchell Whitehead, MD

  AIDS Healthcare Foundation
  Pensacola, Florida, United States
• KM

  Katie L. Mycock, MChem

  Associate Manager, Observational Research
  Adelphi Real World
  Bollington, England, United Kingdom
• NR

  Neil Reynolds, PhD

  Adelphi Real World
  Bollington, England, United Kingdom
• HW

  Hannah Wallis, MS

  Adelphi Real World
  Bollington, England, United Kingdom
• MA

  Mona Amet, MPH

  Adelphi Real World
  Bollington, England, United Kingdom
• AL

  Ann Linskey, PharmD, AAHIVP

  ViiV Healthcare
  Durham, North Carolina, United States
• 

  Jimena Patarroyo, PharmD, AAHIVP

  Senior Medical Science Liaison
  ViiV Healthcare
  Research Triangle Park, North Carolina, United States
• DM

  Deanna Merrill, PharmD, MBA, AAHIVP

  Medical Affairs Scientific Director, Research
  ViiV Healthcare
  Research Triangle Park, North Carolina, United States
• EO

  Edgar T. Overton, MD

  Head Regional Medical Director
  ViiV Healthcare
  Birmingham, Alabama, United States
• 

  Cindy Garris, MS (she/her/hers)

  Senior Director, US Health Outcomes
  ViiV Healthcare
  Durham, NC, United States
• AB

  Andrew P. Brogan, PhD

  Director, US Health Outcomes
  ViiV Healthcare
  San Diego, California, United States